VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Brufsky on CDK 4/6 Inihibitors in Neoadjuvant Breast Cancer Treatment

Adam M. Brufsky, MD, PhD
Published: Thursday, Jun 29, 2017



Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses CDK 4/6 inhibitors in neoadjuvant breast cancer treatment.

In the neoadjuvant setting, using CDK 4/6 inhibitors with hormonal therapy is in the future of breast cancer treatment, particularly with luminal A tumors.

Response trials are currently ongoing that may guide in the decision to use CDK 4/6 inhibitors in this setting.
 


Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses CDK 4/6 inhibitors in neoadjuvant breast cancer treatment.

In the neoadjuvant setting, using CDK 4/6 inhibitors with hormonal therapy is in the future of breast cancer treatment, particularly with luminal A tumors.

Response trials are currently ongoing that may guide in the decision to use CDK 4/6 inhibitors in this setting.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x